Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-14
2007-08-14
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S197000
Reexamination Certificate
active
11518231
ABSTRACT:
The invention describes novel nitrosated and/or nitrosylated H2receptor antagonist compounds, and novel compositions comprising at least one H2receptor antagonist compound that is optionally substituted with at least one NO and/or NO2group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.
REFERENCES:
patent: 3950333 (1976-04-01), Durant et al.
patent: 4279906 (1981-07-01), Frosch et al.
patent: 4283408 (1981-08-01), Hirata et al.
patent: 4293557 (1981-10-01), Shibata et al.
patent: 4705683 (1987-11-01), Dettmar et al.
patent: 4742083 (1988-05-01), Ritchey
patent: 4835281 (1989-05-01), Bod et al.
patent: 4900741 (1990-02-01), Kohler et al.
patent: 5037815 (1991-08-01), Lukacsko et al.
patent: 5102902 (1992-04-01), Mercer
patent: 5112850 (1992-05-01), Benes et al.
patent: 5120746 (1992-06-01), Hirai et al.
patent: 5188839 (1993-02-01), Pearmain et al.
patent: 5229134 (1993-07-01), Mention et al.
patent: 5403830 (1995-04-01), Place
patent: 5407688 (1995-04-01), Place
patent: 5476669 (1995-12-01), Borody et al.
patent: 5541212 (1996-07-01), Bourinbaiar
patent: 5578597 (1996-11-01), Spector et al.
patent: 5656652 (1997-08-01), Davis et al.
patent: 6436975 (2002-08-01), Del Soldato
patent: 6503929 (2003-01-01), Del Soldato
patent: 7189750 (2007-03-01), Assaf et al.
patent: 2003/0027844 (2003-02-01), Del Soldato
patent: 049618 (1982-04-01), None
patent: 224612 (1987-06-01), None
patent: 285681 (1988-10-01), None
patent: 743320 (1996-11-01), None
patent: WO-9407541 (1994-04-01), None
patent: WO-9733576 (1997-09-01), None
patent: WO-9857626 (1998-12-01), None
patent: WO-9944595 (1999-09-01), None
patent: WO-9945004 (1999-09-01), None
Bertinaria et al., Helvetica Chimica Acts, 83(1), 287-299, 2000.
Bourinbaiar et al., Life Sciences, 59(23), PL 365-370 (1996).
Brunton, Goodman and Gilman, The Pharmacological Basis of Therapeutics, 9thEdition, 901-915 (1996). McGraw-Hill.
Chemical Abstracts, 98:215341, “Phenoxyalkylamine Derivates” Teikoku Hormone Mfg, Co. Ltd., JP 58-015945, Registry No. 85856-36-6 (1983).
Cohen et al., Canadian Journal of Ophthalmology, 19(5), 212-214 (1984).
DeFlora, Lancet, 2(8253):993-994 (1981).
Emerson et al., Nueroreport, 13(11), 1407-1410 (2002).
Franekic et al., Mutation Research, 227:13-16 (1989).
Hassan et al., Analytica Chimica Acta, 332:39-48 (1996).
Hirakawa et al., Chem. Pharm. Bull., 46:610-622 (1988).
Hogan, J. Clin. Gastroenterol., 12 (Supl. 2) S21-S28 (1990).
Ichikawa et al., Brit. J. Pharmacol., 122:1230-1236 (1997).
Ichikawa et al., J. Pharmacol., 251:107-111 (1994).
International Search Report for PCT/US99/27207.
Ishikawa et al., European Journal of Pharmacology, 378, 299-310 (1999).
Ivanov et al., J. Pharmacol., 48:297-301 (1996).
Maltz, Clinical Bulletin, 9(4):165-167 (1979).
Marazova et al., Pharm, Pharmacol., 49:791-795 (1997).
Montzka et al., Canadian Journal of Chemistry, 61(8):1771-1777 (1983).
Raskin, The American Journal of Medicine, 106(5B), 3S-12S (1999).
Rice et al., Chemical Abstracts, 97:183 (1982).
Sekiguchi et al., Arzneim. Forsch Drug Res., 43(1):134-138 (1993).
Sekine et al. Chem. Pharm. Bull., 46:610-615 (1988).
Selker, The New England Journal of Medicine, 229(15): 834 (1978).
Siepler et al., Am. J. Hosp. Pharm., 35(2), 141-145 (1978).
Sorba et al., Arzneim. Forsh Drug Res., 47:849-854 (1997).
Trzeciakowski et al., Journal of Ocular Pharmacology, 3(1), 55-61 (1987).
Ares et al. Current Pharm. Des, 4:17-36 (1998).
Al-Ghamdi et al. J. Int. Med. Res., 19:242-248 (1991).
Coruzzi et al. J. Physiol., 94:5-10 (2000).
Koch et al. J. Dig. Dis., 13(1):62-74 (1995).
Naito et al. Arzneim. Forsch/Drug Res., 47(II):845-848 (1997).
Garvey David S.
Letts L. Gordon
Lin Chia-En
Wang Tiansheng
NitroMed Inc.
Powers Fiona T.
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Nitrosated and nitrosylated H 2 receptor antagonist... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrosated and nitrosylated H 2 receptor antagonist..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrosated and nitrosylated H 2 receptor antagonist... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3866867